Less Need Found for Immunosuppressants in gMG After Soliris

Less Need Found for Immunosuppressants in gMG After Soliris

281954

Less Need Found for Immunosuppressants in gMG After Soliris

People with refractory generalized myasthenia gravis (gMG) who responded to Soliris (eculizumab) were able to reduce the use of immunosuppressive therapies, data from an extension study of the Phase 3 REGAIN trial showed. Tapering off immunosuppressants may be considered for those with hard-to-treat gMG who respond to Soliris, the scientists said — which should ease these patients’ treatment-related burden. The analysis was published in the journal Neuromuscular Diseases, in a study titled “Concomitant Immunosuppressive Therapy…

You must be logged in to read/download the full post.